Riskpilot← Back to searchSign inGet full accessTEMPOGENE AS
ASActiveOrg 920431135Forskningsparken Sharelab Gaustadalléen 21, 0349 OsloResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20182 employees
Revenue 2024
NOK 1,5M
-4% vs 2023
EBITDA margin
-57.1%
+35% vs 2023
Equity ratio
57.5%
Financial strength
Net profit 2024
NOK -667K
+32% vs 2023
| Revenue | NOK 1,5M | -4% |
| EBITDA | NOK -862K | +35% |
| Net profit | NOK -667K | +32% |
| Total assets | NOK 5,1M | -8% |
| Equity | NOK 2,9M | -19% |
| Employees | 2 | — |
Legal name
TEMPOGENE AS
Org number
920431135
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
14. februar 2018
Share capital
NOK 52 900
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene. Daglig leder alene.
Company purpose
Kommersialisere bioteknologiske produkter og tjenester, samt alt som hører naturlig til dette.
Address
Forskningsparken Sharelab Gaustadalléen 21, 0349 Oslo
Email
tarjei.lie@tempogene.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 173 | 650 | 153 | 155 | 1 568 | 1 510 |
| Staff expenses | −0 | −250 | −1 212 | −1 470 | −1 793 | −1 785 | −1 544 |
| EBITDA | −1 | −598 | −1 160 | −2 078 | −2 728 | −1 320 | −862 |
| Depreciation & amort. | −0 | −57 | −16 | −0 | −18 | −18 | −18 |
| EBIT | −1 | −655 | −1 176 | −2 078 | −2 746 | −1 339 | −880 |
| Net financials | 0 | 2 | 0 | 1 | −8 | 6 | 26 |
| Profit before tax | −1 | −654 | −1 176 | −2 077 | −2 754 | −1 333 | −855 |
| Tax | −0 | −145 | −259 | −484 | −608 | −360 | −188 |
| Net profit | −1 | −508 | −917 | −1 593 | −2 146 | −973 | −667 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Total assets | 273 | 5 187 | 4 311 | 2 721 | 5 701 | 5 470 | 5 056 |
| Equity | 273 | 4 939 | 4 022 | 2 430 | 3 820 | 3 572 | 2 906 |
| Long-term debt | 0 | 0 | 0 | 0 | 1 500 | 1 506 | 1 500 |
| Short-term debt | 0 | 248 | 289 | 292 | 381 | 392 | 651 |
| Total debt | 0 | 248 | 289 | 292 | 1 881 | 1 898 | 2 151 |
EBITDA margin
-57.1%
This company
15.8%
Market median
-461% vs market
20182024
Equity ratio
57.5%
This company
38.2%
Market median
+51% vs market
20182024
Return on equity
-22.9%
This company
18.4%
Market median
-224% vs market
20182024
Net profit margin
-44.2%
This company
8.1%
Market median
-646% vs market
20182024
Asset turnover
0.30×
This company
1.12×
Market median
-73% vs market
20182024
Debt / equity
0.74×
This company
0.62×
Market median
+19% vs market
20182024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 19.2% | 19.2% | 2022 | |
| Individual | 18.9% | 18.9% | 2022 | |
| Individual | 18.9% | 18.9% | 2022 | |
Stratel As | Company | 11.9% | 11.9% | 2022 |
Liaskjæret Holding As | Company | 9.7% | 9.7% | 2022 |
Startuplab Founders Fund Iii As | Company | 8.5% | 8.5% | 2022 |
Reodor As | Company | 5.1% | 5.1% | 2022 |
| Individual | 2.9% | 2.9% | 2022 | |
Devold Holding As | Company | 1.5% | 1.5% | 2022 |
Hogein As | Company | 1.5% | 1.5% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
TEMPOGENE AS 
GADUS GENETICS ASBoard members of TEMPOGENE AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kaja Helvik Skjærven | Board of Directors | 0 companies |